Group 1: Clinical Trials and Collaborations - The company Henlius (Shanghai Henlius Biopharmaceutical) is collaborating with Carolyn Bertozzi's team to initiate the first human clinical trial next year [2][7] - The therapy being developed is a dual-function sialidase fusion protein therapy aimed at targeting cancer cells [7] Group 2: Scientific Breakthroughs - Carolyn Bertozzi has made significant breakthroughs in bioorthogonal chemistry, which allows for the tracking and modification of specific biomolecules without disrupting natural biological processes [6] - The developed antibody drug targets sialic acid on cancer cells, enhancing the immune system's ability to recognize and eliminate these cells [5][6] Group 3: Impact on Cancer Treatment - The immune therapy developed by Bertozzi's team has the potential to cure certain types of cancer, such as melanoma and lung cancer, which have higher mutation rates and more receptors on their surface [6] - The advancements in cancer immunotherapy are being referred to as a "penicillin moment" for cancer treatment, indicating a significant breakthrough in the field [2]

Financial Performance - The company reported a revenue of 2.82 billion RMB for the six months ending June 30, 2025, representing a year-on-year increase of 2.67% [1] - Gross profit reached 2.199 billion RMB, up 10.47% compared to the previous year [1] - Shareholder profit attributable to the company was 390 million RMB, a slight increase of 0.99% year-on-year [1] - Basic earnings per share were 0.72 RMB [1] Research and Development - The company confirmed R&D expenditures of approximately 999.5 million RMB, an increase of about 170 million RMB from the previous year's 826 million RMB, primarily aimed at enhancing investment in innovative R&D projects to accelerate transformation [1] International Expansion - As of August 22, 2025, the company has successfully launched six products (covering 25 indications) in various countries including China, the US, Europe, Canada, Australia, Indonesia, Mexico, and Bolivia [2] - Four products have been approved in different overseas markets, reaching nearly 60 countries and benefiting over 850,000 patients globally [2] - The company's product "Hanshu" for extensive-stage small cell lung cancer was approved for marketing in the EU in February 2025, marking the second product approved in the EU, indicating strong recognition of the company's innovative products in international markets [2] - In July 2025, the biosimilar HLX14 received a positive review from the European Medicines Agency (EMA), paving the way for its approval in broader overseas markets [2]

Core Insights - The company reported a revenue of 2.82 billion RMB for the six months ending June 30, 2025, representing a year-on-year increase of 2.67% [1] - Gross profit reached 2.199 billion RMB, up 10.47% year-on-year, while net profit attributable to shareholders was 390 million RMB, a 0.99% increase [1] - The company invested approximately 995 million RMB in R&D, an increase of about 170 million RMB compared to the same period last year, focusing on innovative R&D projects to accelerate transformation [1] Group Performance - The overseas product sales revenue was approximately 40.6 million RMB, with profits from overseas products more than doubling compared to the same period last year, driven by the company's international strategy and increased sales in the U.S. market [1] - As of August 22, 2025, the company has successfully launched six products (covering 25 indications) in multiple countries, including China, the U.S., Europe, and others, benefiting over 850,000 patients globally [2] - The product "Hanshu" for extensive-stage small cell lung cancer was approved for first-line treatment in the EU in February 2025, marking the company's second product approved in the EU [2] - The biosimilar HLX14 received a positive opinion from the European Medicines Agency (EMA) in July 2025, paving the way for its market entry in broader overseas markets [2]

截至2025年6月30日止六個月的中期業績公告 上海復宏漢霖生物技術股份有限公司（「本公司」或「復宏漢霖」）董事會（「董事 會」）欣然宣佈根據國際財務報告準則（「國際財務報告準則」）編製的本公司及其附 屬公司（統稱「本集團」或「我們」）截至2025年6月30日止六個月（「報告期」）之未 經審計綜合財務業績。 財務摘要： 1 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Shanghai Henlius Biotech, Inc. 上海復宏漢霖生物技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2696） 1. 截至2025年6月30日止六個月，本集團的總收入約人民幣2,819.5百萬元， 較截至2024年6月30日止六個月約人民幣2,746.1百萬元增加約人民幣73.4 百萬元，增長約2.7%。該收入主要來自藥物銷售，向客戶提供的研究與開 發（「研發」）服務及授權許可收入。 2. 截至2025年6月30日止六個月，本集團確認 ...

Financial Performance - Henlius achieved a revenue of RMB 2.82 billion in 2025 H1, representing a 2.7% year-over-year growth[5, 207, 212] - Product sales reached RMB 2.56 billion in 2025 H1, a 3.1% year-over-year increase[6, 207, 212] - The company's net profit was RMB 386 million, with a net profit margin of 13.8%[5, 6] - Net operating cash inflow reached RMB 770 million, showing a 207% year-over-year growth[6] Business Development & Out-licensing - BD contract cash inflow exceeded RMB 1 billion in 2025 H1, a 280% year-over-year growth[6] - Out-licensing deals include HLX13 (Ipilimumab) to Sandoz for up to USD 300 million, HLX15 (daratumumab) to Dr Reddy's for up to USD 131.6 million, and HANSIZHUANG (serplulimab) to Lotus in South Korea for up to USD 112 million[6, 48] - Recent major out-licensing products contributed cash inflow of approximately RMB 670 million in 1H25[47] Key Products Performance - HANSIZHUANG sales reached RMB 0.6 billion in 2025 H1[6] - HANQUYOU global revenue in 1H2025 was RMB 1.44 billion[146] - HANBEITAI revenue in 1H2025 was RMB 116 million[176] - HANNAIJIA revenue in 1H2025 was RMB 97 million[158] - HANLIKANG revenue in 1H2025 was RMB 274 million[186] - HANDAYUAN revenue in 1H2025 was RMB 27 million[186]

Group 1 - Company Kexing Pharmaceutical is planning to issue H-shares and list on the Hong Kong Stock Exchange, with discussions ongoing with relevant intermediaries, but specific details are yet to be determined [1] - In the first half of 2025, Kexing Pharmaceutical reported revenue of 700 million yuan, a year-on-year decrease of nearly 8%, while net profit attributable to shareholders increased by 576% to 80.34 million yuan [1] Group 2 - Company Junshi Biosciences has completed the administration of the first patient in the U.S. for the international multi-center Phase II clinical study of HLX43, a PD-L1 antibody-drug conjugate for advanced non-small cell lung cancer [2] - The clinical study is also being conducted in China, with plans to expand to Australia and Japan when conditions permit [2] Group 3 - Company Sanofi Biologics announced that shareholders plan to reduce their holdings by a total of up to 3.43%, with specific reductions from various executives and shareholders scheduled between September 15 and December 14, 2025 [3] - This potential reduction may cause short-term fluctuations in the stock price, while the long-term value will depend on the company's core business developments [3] Group 4 - Company Changshan Pharmaceutical reported a net loss of approximately 29.09 million yuan for the first half of 2025, with revenue of about 492 million yuan, a year-on-year decrease of 13.42% [4] - The company needs to focus on business restructuring and improving product competitiveness to enhance performance and profitability [4] Group 5 - Company Tianyao Pharmaceutical reported a revenue of approximately 1.588 billion yuan for the first half of 2025, a year-on-year decrease of 11.81%, with a net profit of about 49.3 million yuan, down 65.28% [5] - The decline in revenue and net profit is attributed to price reductions from centralized procurement and market competition affecting raw materials, alongside a fine exceeding 69 million yuan due to monopoly issues [5]

Core Viewpoint - The company, Junshi Biosciences (复宏汉霖), has announced the completion of the first patient dosing in the United States for its international multicenter Phase II clinical study of HLX43, a PD-L1 targeted antibody-drug conjugate, in patients with advanced non-small cell lung cancer (NSCLC) [1] Group 1 - The Phase II clinical study is also being conducted simultaneously in mainland China, excluding Hong Kong, Macau, and Taiwan [1] - The company plans to conduct clinical trials in Australia and Japan once conditions are met [1]

Core Viewpoint - The company, Fuhong Hanlin (02696), has announced the completion of the first patient dosing in the United States for an international multicenter phase II clinical trial of HLX43, a PD-L1 targeted antibody-drug conjugate, in patients with advanced non-small cell lung cancer (NSCLC) [1] Group 1: Clinical Trial Details - The phase II clinical trial is designed to evaluate the efficacy and safety of HLX43 in patients with advanced NSCLC [1] - The study consists of two phases: the first phase focuses on dose exploration to select an appropriate dose for the second phase, which is a single-arm, multicenter phase II clinical study [1] - The primary objective of the study is to assess the clinical efficacy of HLX43 in advanced NSCLC, with the main endpoint being the objective response rate evaluated by a blinded independent review committee according to RECIST v1.1 criteria [1] Group 2: Market Context - As of the date of the announcement, there are no approved PD-L1 targeted antibody-drug conjugates available in the global market [1]

Core Viewpoint - The company, Junshi Biosciences (复宏汉霖), has announced the completion of the first patient dosing in the United States for an international multicenter phase 2 clinical trial of HLX43, a PD-L1 targeted antibody-drug conjugate, in patients with advanced non-small cell lung cancer (NSCLC) [1] Group 1: Clinical Trial Details - The phase 2 clinical trial is designed to evaluate the efficacy and safety of HLX43 in patients with advanced NSCLC [1] - The study consists of two phases: the first phase focuses on dose exploration to select an appropriate dose for the second phase, while the second phase is a single-arm, multicenter phase 2 clinical study [1] - The primary objective of the study is to assess the clinical efficacy of HLX43 in advanced NSCLC, with the main endpoint being the objective response rate evaluated by a blinded independent review committee according to RECIST v1.1 criteria [1] Group 2: Market Context - As of the date of the announcement, there are no approved PD-L1 targeted antibody-drug conjugates available in the global market [1] - The company plans to conduct clinical trials in Australia and Japan once conditions are suitable, in addition to the ongoing trials in China (excluding Hong Kong, Macau, and Taiwan) [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Shanghai Henlius Biotech, Inc. 上海復宏漢霖生物技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2696） 自願公告 本公告由上海復宏漢霖生物技術股份有限公司（「本公司」）自願作出，以告知 本公司股東及潛在投資者本公司最新業務更新。 本公司董事會（「董事會」）欣然宣佈，近日，一項注射用HLX43（靶向PD-L1 抗體偶聯藥物）（「HLX43」）在晚期非小細胞肺癌(NSCLC)患者中開展的國際 多中心2期臨床研究已完成美國首例患者給藥。該2期臨床研究亦正同步於中 國境內（不包括港澳台地區，下同）開展，本公司擬於條件具備後於澳大利亞 及日本等國家開展臨床試驗。 B. 臨床試驗設計及目的 本研究為一項評估HLX43在晚期非小細胞肺癌(NSCLC)患者的開放、國際 多中心2期臨床試驗，旨在評估HLX43在晚期非小細胞肺癌(NSCLC)患者中 的有效性和安全性 ...